Venatorx Pharmaceuticals Names Scott McConnell, Pharm.D. as Vice President, Medical Affairs
News
Immunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19
– IMM-BCP-01 targets three non-overlapping regions on the Spike protein to provide broad coverage across CDC current and former variants of concern
– IMM-BCP-01 elicits multi-modal activity in pre-clinical testing including ACE2 and non-ACE2 dependent neutralization, as well as natural viral clearance mechanisms
Immunome Reports Third Quarter 2021 Financial Results
– IMM-BCP-01 Progressing Towards IND Filing –
Renovacor Announces Third Quarter 2021 Financial Results and Provides Corporate Update
Debuted as a public company and strengthened liquidity position with $95.1 million in gross proceeds from the business combination with Chardan Healthcare Acquisition 2 Corp and concurrent PIPE financing
Released topline preclinical data demonstrating feasibility of REN-001 to transduce a large animal heart via local infusion at low vector doses
Strengthened company leadership with key appointments including Matthew Killeen, Ph.D., as CSO, and Elizabeth White, Ph.D., as CBO and SVP of Operations
Data from ImmunoGenesis’ Lead Programs Presented in Six Posters at Society for Immunotherapy of Cancer (SITC) Conference
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results
Wellsheet Collaborates with Horizon to Provide Clinicians with a Single View of Key Data and Insights within their EHR Workflow
New Jersey Health Providers Can Access a Near Real-Time Comprehensive View of Patients’ Medical History
Venatorx Pharmaceuticals Announces Collaboration with Roche to Develop New Class of Antibiotics targeting WHO Critical Priority Pathogen
Development of novel antibiotics to circumvent antimicrobial resistance and address increasing threat of superbugs
Phrase Health Announces $3M Investment from Health IT Leaders: LionBird, Vizient, Inc., and BioAdvance
The new investment will enhance growth initiatives, accelerate development, and support additional research to enhance platform capabilities.